Diabetes Care, Vol 21, Issue 9 1470-1474, Copyright © 1998 by American Diabetes Association

ARTICLES

Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients

H Shimizu, T Tsuchiya, N Sato, Y Shimomura, I Kobayashi and M Mori
First Department of Internal Medicine, Gunma University School of Medicine, Japan. hshimizu@sb.gunma-u.ac.jp

OBJECTIVE: Troglitazone, which improves peripheral insulin resistance of experimental diabetic animals and diabetic patients, affects ob gene expression in the adipose tissue of rodents. The present study was undertaken to examine a hypothesis that clinical administration of troglitazone may reduce circulating leptin levels and affect eating behavior in NIDDM patients. RESEARCH DESIGN AND METHODS: Troglitazone was administered at a dosage of 200 mg twice daily for 12 weeks in 20 poorly controlled NIDDM patients. Chronological changes in glycemic control, serum lipids, immunoreactive leptin (IRL) levels, and BMI were measured. Body fat weight was also assessed by bioelectric impedance. RESULTS: Troglitazone significantly decreased fasting plasma glucose, serum immunoreactive insulin, and HbA1c levels. Serum levels of IRL and triglyceride were significantly reduced by troglitazone administered for 4, 8, and 12 weeks. Troglitazone administration significantly increased the BMI in NIDDM patients, and two-thirds of the patients complained of increased hunger after the start of troglitazone administration. CONCLUSIONS: Troglitazone significantly reduces circulating leptin levels at clinical doses. It may affect the eating behavior of poorly controlled NIDDM patients through the improvement of glycemic control and/or the reduction of circulating leptin.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. E Cecil, C. N. Palmer, B. Fischer, P. Watt, D. J Wallis, I. Murrie, and M. M Hetherington Variants of the peroxisome proliferator-activated receptor {gamma}- and {beta}-adrenergic receptor genes are associated with measures of compensatory eating behaviors in young children Am. J. Clinical Nutrition, July 1, 2007; 86(1): 167 - 173. [Abstract] [Full Text] [PDF]

				K. Rautio, J.S. Tapanainen, A. Ruokonen, and L.C. Morin-Papunen Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study Hum. Reprod., June 1, 2006; 21(6): 1400 - 1407. [Abstract] [Full Text] [PDF]

				M A. Soroceanu, D. Miao, X.-Y. Bai, H. Su, D. Goltzman, and A. C Karaplis Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis J. Endocrinol., October 1, 2004; 183(1): 203 - 216. [Abstract] [Full Text] [PDF]

				R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A consensus statement from the American Heart Association and American Diabetes Association Diabetes Care, January 1, 2004; 27(1): 256 - 263. [Full Text] [PDF]

				R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association Circulation, December 9, 2003; 108(23): 2941 - 2948. [Full Text] [PDF]

				N. G. Patel, J. C. Holder, S. A. Smith, S. Kumar, and M. C. Eggo Differential Regulation of Lipogenesis and Leptin Production by Independent Signaling Pathways and Rosiglitazone During Human Adipocyte Differentiation Diabetes, January 1, 2003; 52(1): 43 - 50. [Abstract] [Full Text] [PDF]

				N. I Steinle, W.-C. Hsueh, S. Snitker, T. I Pollin, H. Sakul, P. L St Jean, C. J Bell, B. D Mitchell, and A. R Shuldiner Eating behavior in the Old Order Amish: heritability analysis and a genome-wide linkage analysis Am. J. Clinical Nutrition, June 1, 2002; 75(6): 1098 - 1106. [Abstract] [Full Text] [PDF]

				A. B. Mayerson, R. S. Hundal, S. Dufour, V. Lebon, D. Befroy, G. W. Cline, S. Enocksson, S. E. Inzucchi, G. I. Shulman, and K. F. Petersen The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes Diabetes, March 1, 2002; 51(3): 797 - 802. [Abstract] [Full Text] [PDF]

				P. Raskin, M. Rendell, M. C. Riddle, J. F. Dole, M. I. Freed, and J. Rosenstock A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes Diabetes Care, July 1, 2001; 24(7): 1226 - 1232. [Abstract] [Full Text] [PDF]

				L. S. Phillips, G. Grunberger, E. Miller, R. Patwardhan, E. B. Rappaport, and A. Salzman Once- and Twice-Daily Dosing With Rosiglitazone Improves Glycemic Control in Patients With Type 2 Diabetes Diabetes Care, February 1, 2001; 24(2): 308 - 315. [Abstract] [Full Text]

				A. Katsuki, Y. Sumida, E. C. Gabazza, S. Murashima, M. Furuta, R. Araki-Sasaki, Y. Hori, Y. Yano, and Y. Adachi Homeostasis Model Assessment Is a Reliable Indicator of Insulin Resistance During Follow-up of Patients With Type 2 Diabetes Diabetes Care, February 1, 2001; 24(2): 362 - 365. [Abstract] [Full Text]

				H. E. Lebovitz, J. F. Dole, R. Patwardhan, E. B. Rappaport, and M. I. Freed Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 280 - 288. [Abstract] [Full Text]

				D. Chapelot, R. Aubert, C. Marmonier, M. Chabert, and J. Louis-Sylvestre An endocrine and metabolic definition of the intermeal interval in humans: evidence for a role of leptin on the prandial pattern through fatty acid disposal Am. J. Clinical Nutrition, August 1, 2000; 72(2): 421 - 431. [Abstract] [Full Text] [PDF]

				L. B. Williams, R. L. Fawcett, A. S. Waechter, P. Zhang, B. E. Kogon, R. Jones, M. Inman, J. Huse, and R. V. Considine Leptin Production in Adipocytes from Morbidly Obese Subjects: Stimulation by Dexamethasone, Inhibition with Troglitazone, and Influence of Gender J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2678 - 2684. [Abstract] [Full Text]

				V. Fonseca, J. Rosenstock, R. Patwardhan, and A. Salzman Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial JAMA, April 5, 2000; 283(13): 1695 - 1702. [Abstract] [Full Text] [PDF]

				B. E Wisse, L A. Campfield, E. B Marliss, J. A Morais, R. Tenenbaum, and R. Gougeon Effect of prolonged moderate and severe energy restriction and refeeding on plasma leptin concentrations in obese women Am. J. Clinical Nutrition, September 1, 1999; 70(3): 321 - 330. [Abstract] [Full Text] [PDF]